ADCT vs MGNX vs RCUS vs ABBV

For growth investors, ADC Therapeutics S.

A. (ADCT) is the stronger pick with 14. 9% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). AbbVie Inc. (ABBV) offers the better valuation at 85. 5x trailing P/E (14. 3x forward), making it the more compelling value choice. Analysts rate ADC Therapeutics S. A. (ADCT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +101. 3%, compared to -90. 8% for MacroGenics, Inc. (MGNX). Over 10 years, the gap is even starker: ABBV returned +295. 5% versus ADCT's -87. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 34β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 477% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Arcus Biosciences, Inc. (RCUS) carries a lower debt/equity ratio of 16% versus 66% for MacroGenics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ADC Therapeutics S.

A. (ADCT) is pulling ahead at 14. 9% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: ADC Therapeutics S. A. grew EPS 30. 9% year-over-year, compared to -10. 3% for MacroGenics, Inc.. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AbbVie Inc.

(ABBV) is the more profitable company, earning 6. 9% net margin versus -175. 3% for ADC Therapeutics S. A. — meaning it keeps 6. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for MGNX: 104.

1% to $6. 00.

In this comparison, ABBV (3.

2% yield) pays a dividend. ADCT, MGNX, RCUS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). MacroGenics, Inc. (MGNX) carries a higher beta of 1. 93 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +295. 5%, MGNX: -84. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ADCT is a small-cap quality compounder stock; MGNX is a small-cap quality compounder stock; RCUS is a small-cap quality compounder stock; ABBV is a large-cap income-oriented stock. ABBV pays a dividend while ADCT, MGNX, RCUS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.